Atrial fibrillation (AF) is commonly associated with overweight and obesity. Both conditions have been identified as major global epidemics associated with increased mortality and morbidity. Overweight populations have higher incidence, prevalence, severity, and progression of AF compared with their normal weight counterparts. Additionally, weight change appears to accompany alteration of arrhythmia profile, raising overweight, and obesity as potential targets for intervention. Recent clinical data confirm hypothesis drawn from epidemiological studies that durable weight reduction strategies facilitate effective management of AF. Stable weight loss decreases AF burden and AF recurrence following treatment. Structural remodelling in response to weight loss suggests that reverse remodelling of the AF substrate mediates improvement of arrhythmia profile. Obesity often co-exists with multiple AF risk factors that improve in response to weight loss, making a consolidated approach of weight loss and AF risk factor management preferable. However, weight loss for AF remains in its infancy, and its broad adoption as a management strategy for AF remains to be defined.
Introduction
Atrial fibrillation (AF) is the most common sustained cardiac rhythm disorder in humans 1 and is associated with significant mortality and morbidity. 2 -5 The burden of AF continues to rise globally without signs of waning. 5 The estimated number of people with AF worldwide in 2010 was estimated at 33.5 million. 6 In addition to its effects on health, the growing tide of AF bears significant consequences for the sustainability of existing healthcare structures. 2, 4 Body mass index (BMI) is the most commonly used parameter to determine categories of 'overweight' and 'obese'. Overweight and obese are commonly defined as BMI 25-30 and .30, respectively. The link of AF with obesity is becoming increasingly clear. 7, 8 Obesity is a growing epidemic with its global prevalence doubling over the past 34 years. 9 Based on World Health Organization global estimates, in 2014 .1.9 billion adults were overweight. Of these, 600 million were obese. 9 In Europe and North America, .60% of adults are overweight and of these 20 -30% are obese. 9 Overweight and obesity are associated with significant morbidity and cause .1 million deaths and 12 million life-years of ill health each year in the WHO European Region. 10 A recent meta-analysis estimates a 3.5 -5.3% excess risk of AF for every one unit of BMI increase.
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The rampant rise in AF incidence in the context of an obesity epidemic compels exploration of the link from a clinical perspective. This review initially summarizes the epidemiological evidence suggesting a link between obesity and AF. We then synthesize the current clinical literature surrounding AF mechanisms and place obesity in that context. We finally review the present clinical data examining the impact of obesity and weight management on AF treatment.
Epidemiological associations
Initial links between AF and obesity were observed in perioperative cardiac surgery patients. 12 -15 Since then multiple large epidemiological studies have observed strong associations between obesity and AF ( Table 1 ).
In the Framingham Heart Study, every unit increase in BMI correlated with a 4-5% increase in AF risk. 7 Furthermore, the association persisted even after adjusting for acute myocardial infarction, diabetes, and hypertension. However, the association between AF risk and obesity appeared to be mediated by enlargement of the left atrium, a recognized precursor to AF. This association has been previously demonstrated and provides evidence for the structural remodelling that is associated with obesity and increased AF risk. 16 -18 In the Danish Diet, Cancer, and Health Study, 19 47 589 subjects were prospectively followed for a mean of 5.7 years. Increased BMI was associated with a raised risk of incident AF, with males at a higher risk compared with females. Similar influences of male gender on the association between BMI and AF risk were observed in the Busselton Health Study. 20 The Atherosclerosis Risk in Communities study implies that much of the risk of incident AF is attributable to poor risk factor management. Specifically, 17.9% of the risk of incident AF was attributed to obesity. 21 Most studies investigating the influence of obesity on AF incidence are drawn from older populations with multiple AF risk factors. However, Karosoy et al.
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utilized Danish registry data to follow 271 203 fertile young women (mean age 30.7 years) for a mean of 4.6 years. Even within this population, where most cases were of 'lone AF', obesity remained strongly associated with incident AF compared with the normal population.
The Women's Health Study followed 34 309 participants for a mean of 12.9 years. The investigators found that the risk of incident AF rose proportionately with a rise in BMI. 8 Interestingly, patients that moved from one weight category to the next (i.e. normal weight, overweight, and obese) increased or decreased the risk of incident AF depending on the direction of movement. Furthermore, risk modulation appeared most profound when the movement of weight category occurred during the first 60 months of follow-up. Among those patients that developed AF, raised BMI was associated with development of permanent vs. paroxysmal AF. 23 substrate. These observations suggest a dynamic relationship between substrate factors and body weight.
Obesity is only one of many lifestyle factors that have been observed to contribute to AF development and progression. Often, multiple risk factors subsist within the same patient, and importantly many of them are associated with obesity. Multiple studies have examined the intracardiac substrate in patients with various AF risk factors. They demonstrate extensive atrial remodelling that are similar to the structural and electrical changes that have been identified in patients with structural disease. 25 -27 Hypertension is a main contributor to AF risk and has been identified as such by multiple investigators. In the Multi-Ethnic Study of Atherosclerosis, sustained pre-hypertension (SBP 120 -129 mmHg) and hypertension (SBP ≥130 mmHg) conferred a 1.8-and 2.6-fold increase in the risk of AF, respectively. 28 Data surrounding the impact of blood pressure control on incident or recurrent AF are drawn from studies that examine angiotensin converting enzyme inhibition, and largely suggest that blood pressure control has a modest impact on AF incidence or recurrence. 29 The greatest benefits are afforded to groups with systolic left ventricular dysfunction and clinical heart failure. 30, 31 Other groups that may benefit include patients with left ventricular hypertrophy 32 and AF patients undergoing electrical cardioversion. 33, 34 Similarly, obstructive sleep apnoea is commonly associated with obesity and has a prevalence of 40-50% in the AF population. 35 There is emerging evidence that treatment of OSA greatly enhances AF-free survival in populations having electrical, 36 pharmacological, 37 or ablative 38 attempts to restore sinus rhythm.
Atrial fibrillation is also common in the diabetic population, with AF risk linked to diabetes duration and glycaemic control. 39 -41 However, in the Women's Health Study diabetes was not an independent risk factor for AF, with much of the risk mediated by obesity and hypertension. 42 Data on the impact of hyperlipidaemia on AF incidence are less consistent. Studies demonstrate variable associations between AF incidence and lipid profiles. Associations may be due to links with coronary artery disease, physical activity and systemic inflammation, which are all known to predispose to AF. Weight loss is inevitably paralleled by improvement of other cardio-metabolic risk factors, 43 -45 making it challenging to quantify the risk conferred independently by each factor. However, weight loss strategies provide an opportunity to synchronously address multiple AF risk factors, and thus may have a cumulative impact on the electrophysiologic substrate. The Framingham Heart Study has indicated that besides hypertension and diabetes, familial history of AF was also an independent risk factor in an individual. 46 Atrial fibrillation has been investigated with genome-wide association studies identifying a nucleotide polymorphism at chromosome 4q25. 47 More recently, several new risk loci have been identified. 48 Overall, it is increasingly clear that a genetic predisposition contributes to the risk of developing AF. The precise mechanism, however, whereby for example 4q25 acts to promote AF in humans is not fully understood.
Mechanisms of atrial fibrillation
Moe et al. initially posed a model for AF that consists of multiple wavelets that dynamically divide and coalesce over the atrial myocardium. Hassiguerre et al. reported that pulmonary vein ectopy plays is central in AF pathophysiology, 49 and forms the cornerstone of AF ablation strategies to date. 50 There is also considerable evidence that arrhythmic episodes are of themselves capable of electrically remodelling the atria and thus enable a more suitable substrate for AF. 51 Finally, alterations of autonomic tone have commonly been implicated in the AF substrate. Adrenergic tone increases triggered activity 52 while vagal tone abbreviates the atrial refractory period non-uniformly across the atrium. 53 These perturbations enable fibrillatory activity. While the pulmonary veins appear to play a central role in paroxysmal AF, a complex interaction between triggers and a remodelled atrial substrate seem necessary to sustain persistent AF. 54 Recent mapping studies, utilizing complex data processing techniques have implied that rotors, regions of singularity that drive local activation, play important roles in persistent AF. 55 -58 Yet, their temporal stability and driving role remains contentious. Stretch is a major contributor to the remodelled atria and has been characterized across multiple clinical contexts. These include atrio-ventricular dysynchrony, 59 ,60 atrial flutter, 61 heart failure, 62 -65 atrial septal defects, 61, 66 valve disease, 64, 67, 68 hypertension, 26 and obstructive sleep apnoea. 25 Even transient stretch has been shown to increase signal complexity at the pulmonary vein-atrial junction. 69 Furthermore, atrial remodelling appears reversible in some contexts following elimination of the inciting cause. 67 There is increasing evidence that atrial fibrosis is a fundamental common structural finding in AF patients with structural heart disease as well as with 'lone' AF. 70 In a post-mortem autopsy study investigating left and right atrial tissue samples from patients with paroxysmal, permanent and no AF, the extent of fibrosis showed a strong correlation with the presence of AF at all tissue sampling locations. 71 As an alternative explanation, the bi-atrial fibrotic process has recently been described to be the consequence of a primary fibrotic atrial cardiomyopathy (FACM).
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Both atrial remodelling and substrate progression have been observed in cases remote from an obvious precipitant. 74, 75 These findings raise the potential of previously under-recognized or overlooked AF risk factors. Obesity has also been associated with haemodynamic, structural, and electrical derangements of the atria. 76 It is in this context that obesity raises its profile as an AF risk factor that may be targeted for therapy, with potential for reverse remodelling of the AF substrate.
Mechanisms of atrial fibrillation in obesity
Several mechanisms have been identified to explain the association between obesity and AF ( Figure 1) . Firstly, as previously noted, weight loss affects other established AF risk factors that impact on the AF substrate. Additionally, impaired diastolic function, inflammation, and pericardial fat have emerged as important players in the AF mechanism in obesity ( Figure 2) . Epidemiological studies show a strong link between obesity, diastolic impairment, and AF incidence. 8, 77 Investigators have observed more persistent AF, 77 more severe AF symptoms, 77 and poorer ablation outcomes among patients with diastolic impairment. 78 Others have shown that successful catheter ablation results in improved
The role of obesity in atrial fibrillation diastolic function. 79 Increased left atrial pressure and atrial size, in association with longer left atrial and pulmonary vein effective refractory periods, have been identified in obese cohorts. 80 The link of diastolic impairment with obesity has been verified in a clinical setting, where diastolic impairment improved in response to weight loss. 43 There is mounting evidence for the arrhythmogenic impact of cardiac fat depots on neighbouring tissue. A recent analysis of 2317 participants from the Framingham Heart Study Offspring and Third Generation Cohorts showed an association of total pericardial fat volume quantified by computed tomography with prevalent AF. 81 The association persisted even after adjusting for other measures of obesity and other AF risk factors. Other groups have made similar observations. 82, 83 Wong et al. utilized magnetic resonance imaging to quantify pericardial fat in patients having AF ablation. Cardiac fat quantity correlated with AF severity and AF recurrence following ablation. 84 Recent work suggests that fat overlying the left atrium may identify dominant frequency sites or regions of complex fractionated atrial electrograms in persistent AF. 85 Thus fat deposits overlying the atrial myocardium may prove to be clinically important for catheter ablation. The paracrine effect of fat deposits, acting via inflammatory mediators and adipokines, have been used to explain these observations. 86 Additionally, local fat depots may exert an arrhythmogenic effect on contiguous atria. 84 Inflammation and resultant fibrosis has also been implicated in the remodelling process. Several links between obesity and an increased basal inflammatory state exist in the literature. 87 Clinical studies have noted a decline in high sensitivity CRP titres, consistent with a dampened inflammatory response, in association with weight reduction. 45 Electro-anatomical studies have identified extensive regions of scar in the atria of AF patients. 88 More recently, magnetic resonance imaging has been used to characterize and quantify atrial scar in AF patients, with a suggestion that scar burden correlates with ablation success. Severe scarring has been claimed to identify increasingly diseased substrates that are less amenable to rhythm control strategies. 88 -91 Weight loss and risk factor modification may directly impact treatment success by facilitating substrate regression and attenuating disease progression. Leptin and its associated biomarker adiponectin are both closely related with obesity and have recently also been implicated with AF. Animal models demonstrate that Leptin signalling is involved in atrial fibrosis and AF. 92 In The Cardiovascular Health Study, 3190 patients aged ≥65 years were followed for a median of 11.4 years. 93 Adiponectin levels were independently associated with incident AF. However, it remains unclear whether these are markers of failed regulatory pathways that lead to AF or are directly involved in AF pathogenesis.
In some cases, a fibrotic atrial substrate due to FACM may interact with body weight to predispose obese and overweight patients to AF. This hypothesis is dependent on obesity acting as a 'modulating factor' on an already pro-arrhythmic atrial substrate. The role of modulating factors was recently posed in the post-surgical scenario, where incident AF was associated with higher degrees of fibrosis, Figure 1 The association between obesity and AF is evident from a combination of epidemiologic, clinical, and mechanistic data. This figure presents the central findings that support this association. AF, atrial fibrillation; BMI, body mass index. C.J. Nalliah et al.
implying that cardiac surgery had a modulating effect on a subclinical AF substrate. 94 These various aspects of atrial remodelling were investigated in an ovine model of obesity. 95 Study animals were placed on high caloric diets that resulted in weight gain. The animals underwent electrophysiologic studies, cardiac magnetic resonance imaging, and histology at baseline, 4 and 8 monthly intervals. Weight gain resulted in progressive remodelling characterized by conduction heterogeneity, isochronal crowding, and increased AF (spontaneous and inducible). This was associated with bi-atrial enlargement, increase in biventricular mass, and pericardial fat volumes. Histology showed increased atrial interstitial fibrosis, inflammation, myocardial lipidosis, and expression of pro-fibrotic mediators. With chronic obesity, these animals not only demonstrate progressive atrial remodelling but in areas adjacent to extensive pericardial fat there was infiltration of the local atrial myocardium by fat cells. 96 This latter observation was predominantly seen over the posterior left atrium and may represent a unique component of the substrate for AF. Furthermore, weight loss in overweight animals was paralleled by improved electrophysiologic, structural, and histologic cardiac characteristics. 96 These observations highlight the AF substrate's capacity for progression and regression in response to changing body weight and underpins the clinical rationale for weight loss in AF management.
Clinical perspective
Abed et al. clinically evaluated the impact of weight reduction on AF symptoms. 43 Obese patients with paroxysmal AF were randomized to aggressive risk factor management in a physician led clinic or to standard therapy that consisted of weight loss advice. The physician led clinic addressed hypertension, dyslipidaemia, glycaemic control, obstructive sleep apnoea, tobacco, and alcohol use, in addition to targeted weight loss strategies. Patients were followed for 15 months, with assessment of AF burden, symptom score and cardiac structure utilizing transthoracic echocardiography. At 6, 12, and 15 months, 91, 73, and 54% of participants, respectively, remained in the study. Weight loss was paralleled by improved profiles of co-existing cardiovascular risk factors, reduction of AF burden (frequency and duration), and symptom severity. Importantly, interventricular septal thickness and left atrial area decreased, signifying structural remodelling in response to weight loss. Although anthromorphometric indices mildly improved in the control group, changes were more dramatic in the intervention group, with between-group differences evident as early as 3 months after commencement of the trial. Only the intervention group experienced reduction of AF frequency and duration. Weight reduction and risk factor management institutes a process of substrate remodelling that leads to a reduction in AF burden. The 'Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study' (LEGACY) investigated the long-term impact of weight loss on AF symptoms and burden. 45 Three hundred and fifty-five patients that were offered goal-directed weight management strategies were followed for a mean of 4 years. Patients were divided into tertiles based on proportion of loss of body weight (Group 1: .10%, Group 2: 3-9%, and Group 3: ,3%). The impact of weight Figure 2 Mechanisms of atrial fibrillation in obesity.
The role of obesity in atrial fibrillation fluctuation, defined as weight changes between consecutive visits was also evaluated (wide: .5%, average: 2 -5%, stable: ,2%). Of 179 patients with weight-fluctuations, 54% had ,2%, 68 had 2 -5%, and 57% had .5% weight fluctuation. Notably, a variety of rhythm control strategies that included medical therapy, electrical cardioversion, and ablation were utilized. A dose -response relationship was observed between weight loss and freedom from AF. At final follow-up, 45.5% of Group 1, 22.2% of Group 2, and 13.4% of Group 3 (P , 0.001) remained free from arrhythmia without antiarrhythmic drugs or ablation (Figure 3) . Weight loss of at least 10% was associated with a 6-fold greater probability of arrhythmiafree survival (compared with ,3% weight loss). Greater weightfluctuations were also associated with poorer arrhythmia-free outcomes. At final follow-up, 85.2% of patients with ,2% weightfluctuation, 59% with 2 -5% weight-fluctuation, and 44% with .5% (P , 0.001) remained arrhythmia free (Figure 4) . After multivariate analysis, .5% weight-fluctuation was associated with increased risk of AF recurrence when compared with ,2% weightfluctuation (hazard ratio, HR 2.06, 95% confidence interval, CI 1.0-4.3; P ¼ 0.02). Additionally, stable weight was associated with improved structural remodelling, risk factor profiles, inflammatory markers, and symptom scores. Noteworthy, are that 84% patients that achieved weight loss of .10% with little weight-fluctuation attended the weight management clinic, highlighting its critical role for optimal, stable, and durable weight loss. Recent studies have shown that the AF substrate continues to progress even after restoration of sinus rhythm utilizing ablative strategies. 75 While recurrence of pulmonary vein conduction is often cited as the cause for recurrence, this usually occurs early following the procedure. Late recurrence points to progression of the AF substrate. Strategies that affect the underlying substrate need to be developed to further improve treatment outcomes. The 'Aggressive Risk Factor Management for Atrial Fibrillation and Implications for the Outcome of Ablation study' (ARREST-AF cohort study) examined the impact of risk factor management following catheter ablation of AF. 44 Of 149 obese patients undergoing AF ablation, 61
opted for risk factor management and 88 did not. Among patients having risk factor management, the most marked improvements were seen with respect to hypertension and glycaemic control, despite improvements across the board. In addition to improved anthro-morphometric profiles, cardiac structure, and symptom scores, patients having risk factor management had superior freedom from arrhythmia recurrence. Following multivariable analysis, the only predictors of recurrence were non-paroxysmal AF and allocation to the control group (control vs. risk factor management group: HR 2.3 (95% CI 1.5 to 3.6) P , 0.001). Thus, reverse atrial remodelling in response to weight loss optimizes results following ablation.
Weight loss and weight-fluctuation appear to be directly and proportionately associated with regression of the AF substrate ( Figure 2 ). Weight loss persists as a major contributing factor to arrhythmia-free survival, regardless of the antiarrhythmic strategy utilized. The dynamic nature of this relationship highlights the need for durable weight loss strategies to ensure long-term antiarrhythmic benefit. Thus, weight loss must form a critical component of AF treatment in the obese patient. These clinical findings elegantly The role of obesity in atrial fibrillation fit with population data that correlate weight and weight-fluctuation with incident AF and AF progression ( Table 2) .
Conclusion
Recent clinical data married with known epidemiological associations and insights from basic science, mandate incorporation of weight reduction strategies to optimize chances of durable rhythm control. Weight loss attenuates the AF substrate to decrease AF burden and likely impedes progression to more persistent forms of AF. However, the interplay is a complex one, and is likely influenced by risk factors associated with obesity, as well as by the degree of any primary process. Thus, it is important for clinicians and patients to embrace a consolidated risk factor management approach to management of AF.
Compliance and durability of weight loss are the major impediments to risk factor management. Although weight reduction and concomitant management of risk factors impacts the AF substrate, the ability to achieve this outside of a single site is yet to be determined. Clinical data from the LEGACY trial suggest that dedicated physician led clinics may facilitate such an approach and maximize chances for durable results. 45 The link between obesity and AF presents policy makers with a prime opportunity to curb the growing tide of AF by instituting preventative strategies that target overweight at risk populations. Previous studies have evaluated the impact of population strategies on weight and subsequent cardiovascular outcomes in general. 97 Though cardiovascular outcomes remained similar, weight loss, and risk factor profiles were improved in populations that received intervention. However, the impact of population weight loss on AF incidence has not been assessed. Successful population initiatives that decrease rates of obesity and subsequent AF can profoundly affect community health and health expenditure. 4, 6 In addition to direct reductions in AF-related morbidity, AF-related heart failure hospitalizations, 2 and stroke with its consequent neurological disability 1 also stand to be impacted. Further work is needed to determine the feasibility and impact of primary prevention of AF on a population wide basis. Furthermore, the cost effectiveness needs to be evaluated and balanced with rising hospitalization and healthcare costs for AF and AF-related conditions.
